Saint Louis University, Division of Infectious Diseases, Allergy, and Immunology, Department of Internal Medicine, 1100 S. Grand Blvd., Edward A. Doisy Research Center - 8th Floor, Saint Louis, MO 63104, United States.
EpiVax, Inc., 188 Valley Street, Suite 424, Providence, RI 02909, United States.
Vaccine. 2019 Aug 23;37(36):5371-5381. doi: 10.1016/j.vaccine.2019.07.033. Epub 2019 Jul 19.
Influenza world-wide causes significant morbidity and mortality annually, and more severe pandemics when novel strains evolve to which humans are immunologically naïve. Because of the high viral mutation rate, new vaccines must be generated based on the prevalence of circulating strains every year. New approaches to induce more broadly protective immunity are urgently needed. Previous research has demonstrated that influenza-specific T cells can provide broadly heterotypic protective immunity in both mice and humans, supporting the rationale for developing a T cell-targeted universal influenza vaccine. We used state-of-the art immunoinformatic tools to identify putative pan-HLA-DR and HLA-A2 supertype-restricted T cell epitopes highly conserved among > 50 widely diverse influenza A strains (representing hemagglutinin types 1, 2, 3, 5, 7 and 9). We found influenza peptides that are highly conserved across influenza subtypes that were also predicted to be class I epitopes restricted by HLA-A2. These peptides were found to be immunoreactive in HLA-A2 positive but not HLA-A2 negative individuals. Class II-restricted T cell epitopes that were highly conserved across influenza subtypes were identified. Human CD4 T cells were reactive with these conserved CD4 epitopes, and epitope expanded T cells were responsive to both H1N1 and H3N2 viruses. Dendritic cell vaccines pulsed with conserved epitopes and DNA vaccines encoding these epitopes were developed and tested in HLA transgenic mice. These vaccines were highly immunogenic, and more importantly, vaccine-induced immunity was protective against both H1N1 and H3N2 influenza challenges. These results demonstrate proof-of-principle that conserved T cell epitopes expressed by widely diverse influenza strains can induce broadly protective, heterotypic influenza immunity, providing strong support for further development of universally relevant multi-epitope T cell-targeting influenza vaccines.
全球范围内的流感每年都会导致大量发病和死亡,当新型菌株进化到人类免疫幼稚时,还会引发更严重的大流行。由于病毒的高突变率,每年都必须根据流行株的情况生成新的疫苗。迫切需要新的方法来诱导更广泛的保护免疫。先前的研究表明,流感特异性 T 细胞可以在小鼠和人类中提供广泛的异型保护性免疫,支持开发针对 T 细胞的通用流感疫苗的合理性。我们使用最先进的免疫信息学工具来识别在 50 多种广泛多样化的甲型流感株(代表血凝素 1、2、3、5、7 和 9 型)中高度保守的假定泛 HLA-DR 和 HLA-A2 超型限制性 T 细胞表位。我们发现了在流感亚型中高度保守的流感肽,这些肽也被预测为 HLA-A2 限制的 I 类表位。这些肽在 HLA-A2 阳性但不是 HLA-A2 阴性的个体中被发现具有免疫反应性。还鉴定了在流感亚型中高度保守的 II 类限制性 T 细胞表位。人类 CD4 T 细胞对这些保守的 CD4 表位有反应,并且表位扩展的 T 细胞对 H1N1 和 H3N2 病毒都有反应。用保守表位脉冲的树突状细胞疫苗和编码这些表位的 DNA 疫苗在 HLA 转基因小鼠中进行了开发和测试。这些疫苗具有高度的免疫原性,更重要的是,疫苗诱导的免疫可以预防 H1N1 和 H3N2 流感的挑战。这些结果证明了一个原则性的证明,即广泛多样化的流感株表达的保守 T 细胞表位可以诱导广泛的保护异型流感免疫,为进一步开发具有普遍相关性的多表位 T 细胞靶向流感疫苗提供了强有力的支持。